Advanced searches left 3/3

Cardiorenal Syndrome - Crossref

Summarized by Plex Scholar
Last Updated: 10 September 2022

* If you want to update the article please login/register

Severe myocarditis as a cause of the formation of cardiorenal syndrome in a patient with refractory rheumatoid arthritis

Traditionally, most researchers believed that the most common rheumatoid arthritis sign in cardiac extraarticular disease is pericarditis. There is also increasing evidence that inflammatory cytokines in RA may trigger chronic myocardial dysfunction, contributing to heart failure in a chronic heart disease epidemic. Myocarditis and cattle were complete declines in myocarditis and cattle during a period of highly effective treatment of refractory rheumatoid arthritis with simple antirheumatic drugs and the successful use of biological therapy.

Source link: https://doi.org/10.47360/1995-4484-2022-495-500


Abstract A3: Possible Differential Effects Of Angiotensin Receptor-neprilysin Inhibitor And Angiotensin Receptor Blocker Against Hypertension And Cardiorenal Injury In A Mouse Model Of Cardiorenal Syndrome

Although evidence is building on the therapeutic effects of ARNI on heart failure and hypertension, the effects of ARNI on kidney disease or CRS are disputed. Despite the effectiveness of the antihypertensive drug, the ARNI group was most effective in preventing the decline in cardiac contraction and cardiac fibrosis in ANS mice. In addition, the results of kidney RNA sequencing analysis revealed that the receptor for advanced glycation end-products signaling pathway was activated in the kidney of the ARNI group in comparison to the Val M and Val H groups. Conclusions: The ARNI group had better cardioprotective results than valsartan treatment regimens, but not enough kidney protection. These findings indicated that the relationship between the antihypertensive effects and the organ protective effects of cardiovascular injury in CRS pathology can be different between angiotensin II receptor blocker and ARNI.

Source link: https://doi.org/10.1161/hyp.79.suppl_1.a3


Abstract 084: Growth Stress And Cardiorenal Syndrome: Effect Of Renal Insufficiency On Blood Pressure And Cardiac Remodeling In Juvenile Rats

Pediatric patients with chronic kidney disease may suffer from many of the comorbidities associated with CKD in adults, including hypertension and cardiovascular pathology, as well as delayed somatic growth. Rats from the Sprague Dawley laboratory were weighed and underwent nuclear magnetic resonance imaging to determine body mass and composition, and were then assigned to nae, Sham or 5/6 nephrectomy groups. The 5/6Nx rats had less somatic growth than sham rats, resulting in less somatic growth than sham rats. In 5/6Nx rats than sham rats, the final body weight was lower. Similarly, the tibialis length in 5/6Nx rats was shorter than sham rats, but not sham rats. According to these studies, 5/6Nx surgery in juvenile SD rats can recapitulate the characteristics of pediatric CRS and CKD-related growth impairment. In the absence of hypertension, adult male 5/6Nx SD rats in our earlier studies developed cardiac hypertrophy.

Source link: https://doi.org/10.1161/hyp.79.suppl_1.084


Abstract P324: Clinical Outcomes And 30-day Readmissions For Heart Failure With Preserved Ejection Fraction And Cardiorenal Syndrome: A Multicenter Database Analysis.

Background: Literature on cardiorenal syndrome findings in heart failure with a preserved ejection fraction is limited. Objective: This report was designed to characterize CRS patients' medical events and 30-day readmission rates with HFpEF. Out of the 1,530,749 index HFpEF-CRS hospitalizations, 1,295,302 had CKD stage I-IV and 281,689 had CKD stage V+. However, CRS with CKD V+ was still higher than CRS with CKD I-IV compared to CRS with CKD I-IV. Compared to the CKD I-IV subgroup, the HFpEF with CKD V+ had a significant 30-day readmission rate on a 30-day readmission rate. In comparison to CKD V+, the most common etiologies associated with 30-day readmissions among CKD I-IV include cardiovascular disease and infectious diseases. Conclusion: Among HFpEF-CRS hospital encounters, the occurrence of CKD stages is linked to increased 30-day readmission rates and all-cause mortality. These results show that patients with CRS should be monitored closely during hospital admissions to prevent life-threatening complications.

Source link: https://doi.org/10.1161/hyp.79.suppl_1.p324


Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome

In the case of chronic kidney disease, cardiovascular disease is extremely common. A typical cardiac pathology in CKD is uemic cardiomyopathy. CKD patients are also susceptible to heart rhythm problems, particularly atrial fibrillation. Traditional CV risk factors as well as established CKD-associated CV risk factors such as anemia are insufficient to explain CV difficulties in the CKD population. Impaired renal excretory function is a result of a accumulated accumulation of uremic retention solutes. In recent years, direct cardiotoxicity of uremic toxins has been on the rise.

Source link: https://doi.org/10.3390/toxins10090352


Value of Combined Plasma NGAL, Cystatin C and NT-proBNP in the Diagnosis of Cardiorenal Syndrome Type 1

Background: The occurrence of acute kidney disease or acute decompensated heart failure in the setting of acute heart arrest or acute decompensated heart failure is a common occurrence and has been described as cardiorenal syndrome 1 (Chester syndrome 1). One of the first biomarkers of acute kidney injury due to ischemia or renal impairment is Neutrophil gelatinase-associated lipocalin in the blood and urine. The department of Cardiovascular resuscitation and Interventional cardiology at Ho Chi Minh City 115People Hospital from November 2018 to May 2019 had 139 patients with AHF or ADHF in the department of Cardiovascular resuscitation and Interventional cardiology, according to Methods. Conclusions: In the diagnosis of CRS1 in patients with AHF or ADHF, the combined plasma NGAL, Cystatin C, and NT-pro BNP is a high value.

Source link: https://doi.org/10.51505/ijmshr.2022.6306


Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway

Following acute kidney injury, cardiorenal syndrome type 3 is a heart disease epidemic. Although many studies have reported that inflammation, oxidative stress, and cardiomyocyte death play a role in cardiac pathophysiological changes during CRS-3, they do not have a non-bias approach to find out the primary mediator of cardiac dysfunction. Besides that, Mouse Inflammation Array Q1 revealed IL-6 as the upstream regulator of Grb2 upregulation after AKI. These effects were negligible in cardiomyocyte damage and mitochondrial bioenergetics impairment in cardiomyocytes treated with a Grb2 inhibitor, although they were not negligible in cardiomyocyte damage and mitochondrial bioenergetics impairment.

Source link: https://doi.org/10.3389/fcell.2021.630412


Cardiorenal Syndrome at Different Stages of Chronic Kidney Disease

The heart and kidney should be regarded not only as individual organs but rather as a dipole with multiple interconnections, according to the cardiorenal syndrome's central theory. The interaction between the heart and kidney appears to be multifactorial: cardiac function, regulation of extracellular mass, blood pressure, and renal sodium utilisation are all important factors that determine crosstalk between the two organs. Though the prevalence of the CRS is high, large clinical trials on heart failure have only partially addressed this topic. Since a holistic approach would change the syndrome's course and therefore improve the CRS' prognosis, multiple factors that contribute to the CRS's pathogenesis are investigated in detail in an attempt to better understand this syndrome and address effectively its various elements.

Source link: https://doi.org/10.1177/039139880703000703


Echocardiographic Patterns in Severe Chronic Kidney Disease with Type 4 Cardiorenal Syndrome Patients

This study was intended to investigate echocardiographic characteristics in type 4 cardiorenal syndrome patients with severe chronic kidney disease CKD. For severe CKD with male predominant, there were 58. 9 percent of the patients with type 4 cardiorenal syndrome in the sixth decade. In severe CKD in type 4 cardiorenal syndrome patients, severe CKD, arrhythmia, and heart failure were all present in a high incidence of CKD. Mean systolic blood pressure was 178. 2 mmHg & mean diastolic blood pressure was 97. 7 percentu00b15. 9 mmHg among the study participants, meaning systolic blood pressure was 178. 2 mmHg & mean diastolic blood pressure was 117. 7 mmHg & mean diastolic blood pressure was 178. 7 mmHg. The study found that a Careful review of echocardiographic findings in patients with type 4 cardiorenal syndrome could reveal the signs of cardiovascular changes. The overwhelming rise of blood pressure and treating it properly is evident from this latest analysis, which shows that the majority of the patients with type 4 CRS with severe CKD experienced left ventricular hypertrophy, so regular 24-hour ambulatory blood pressure monitoring may be recommended to address the unusual rise in blood pressure and treat it properly.

Source link: https://doi.org/10.3329/taj.v35i1.61134

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions